Targeting TGF-β for treatment of osteogenesis imperfecta

BACKGROUND: Currently, there is no disease-specific therapy for osteogenesis imperfecta (OI). Preclinical studies demonstrate that excessive TGF-β signaling is a pathogenic mechanism in OI. Here, we evaluated TGF-β signaling in children with OI and conducted a phase I clinical trial of TGF-β inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, I-Wen, Nagamani, Sandesh C.S., Nguyen, Dianne, Grafe, Ingo, Sutton, Vernon Reid, Gannon, Francis H., Munivez, Elda, Jiang, Ming-Ming, Tran, Alyssa, Wallace, Maegen, Esposito, Paul, Musaad, Salma, Strudthoff, Elizabeth, McGuire, Sharon, Thornton, Michele, Shenava, Vinitha, Rosenfeld, Scott, Huang, Shixia, Shypailo, Roman, Orwoll, Eric, Lee, Brendan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970679/
https://www.ncbi.nlm.nih.gov/pubmed/35113812
http://dx.doi.org/10.1172/JCI152571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970679/
https://www.ncbi.nlm.nih.gov/pubmed/35113812
http://dx.doi.org/10.1172/JCI152571

Ejemplares similares